Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | EIF4A3 | P38919 | 5/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403427 | 0.80 | HCAR3 (0.43) | FABP3FABP4EIF4A3HCAR2HCAR3 | |
| SCHEMBL4552206 | 0.75 | GABRA1 (0.31) | GABRA1 | |
| SCHEMBL1044787 | 0.74 | NOTUM (0.41) | NOTUMHCAR2DAO | |
| SCHEMBL31386913 | 0.71 | NOTUM (0.39) | EIF4A3NOTUMHCAR2DAO | |
| SCHEMBL3060385 | 0.71 | KDM4E (0.39) | NOTUMHCAR2DAOIL1BGABRA1 | |
| SCHEMBL3105456 | 0.71 | NOTUM (0.39) | NOTUMHCAR2DAO | |
| SCHEMBL6622235 | 0.71 | NOTUM (0.39) | NOTUMHCAR2DAO | |
| SCHEMBL20258124 | 0.69 | LMNA (0.34) | GABRA1GABRB1 | |
| SCHEMBL22066874 | 0.68 | TSHR (0.45) | — | |
| SCHEMBL19350085 | 0.68 | ADORA1 (0.39) | NOTUMHCAR2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | FABP3 4741/4885FABP4 4755/4885EIF4A3 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.